video

sound

Persian Version

View:

145

Download:

95

Cites:

Information Journal Paper

Title

SIMVASTATIN-INDUCED RENAL PROTECTION AGAINST ISCHEMIA-REPERFUSION INJURY MEDIATED BY ACTIVATION OF ATP-SENSITIVE POTASSIUM CHANNELS

Pages

 Start Page 7 | End Page 13

Abstract

 Background & Aim: Renal dysfunction due to ISCHEMIA-REPERFUSION (I/R) injury is a common problem following renovascular surgery or KIDNEY transplantation. There is a lot of emerging evidence that statins, which are HMG-COA reductase inhibitors, have renal protective effects against ISCHEMIA-REPERFUSION injury, but the exact mechanism of their protective effect has not been detected properly. This study examined whether SIMVASTATIN reduces I/R injury in KIDNEY. In addition, we investigated whether the observed renal protective effect of SIMVASTATIN is due to the activation of ATP-sensitive potassium (KATP) channels by using selective antagonist glibenclamide. Material and Method: In this experimental study, male wistar rats(150-200 g) were randomized into five groups while their right KIDNEYs had been removed 3 weeks prior to the study: sham operated, I/R group, I/R pretreated with SIMVASTATIN (20mg/kg/day) for 3 days by gavage, SIMVASTATIN + glibenclamide(0.3mg/kg ip) +I/R and glibenclamide +I/R. The I/R injury was induced by clamping the left renal artery for 45 minutes followed by reperfusion for 2 hours. For statistical comparison,one-way ANOVA, Mann-Whitney test and Tukey were used and p<0.05 and p<0.01 were considered significant. Results: In I/R group, the level of both BUN and creatinin, as indices of renal cell damage, were significantly increased compared with the sham-operated group. However, these increases were significantly inhibited by the treatment with SIMVASTATIN. SIMVASTATIN also improved the renal histological damage compared with the IR group (p<0.05). Glibenclamide, the KATP channel inhibitor, significantly decreased the protective effect of SIMVASTATIN (p<0.01).Conclusion: SIMVASTATIN, as an HMG-COA reductase inhibitor, has renal protective effects against ISCHEMIA-REPERFUSION injury independent of its lipid–lowering properties.This protective effect is mediated via activation of the adenosine triphosphate-sensitive potassium channels, and glibenclamide as a KATP channel inhibitor reduces this benefical effect of SIMVASTATIN.

Cites

  • No record.
  • References

  • No record.
  • Related Journal Papers

    Related Seminar Papers

  • No record.
  • Related Plans

  • No record.